Samsung and Alcedis Link Wearable Sensors to Clinical Trial Endpoints

*Samsung will feed biometric data from its devices into Alcedis-managed trials to cut cost and time in drug and device studies.*

Samsung Electronics has formed a partnership with Alcedis, a clinical research organization focused on digital trials, to convert raw sensor readings from wearables into accepted endpoints for pharmaceutical and medical studies. The move places consumer-grade hardware directly into regulated evidence generation.

Alcedis specializes in data-driven trial designs that replace or supplement traditional site visits with continuous remote capture. Samsung brings the hardware and the data pipelines already present in its consumer devices. Together the two companies aim to turn heart-rate variability, activity counts, sleep metrics and similar signals into measurements regulators and sponsors will accept as primary or secondary endpoints.

The partnership announcement states the goal is efficiency: fewer patients required to travel to trial sites, lower per-patient costs, and shorter overall study timelines. No specific device models, data formats, or regulatory filings were named in the release.

Technical scope

Wearables already collect the raw signals at scale. The remaining work lies in validation—mapping those signals to clinical outcomes with enough statistical rigor that a trial sponsor can rely on them in a submission. Alcedis’s role is to design the protocols and statistical plans that meet that standard; Samsung’s role is to supply the sensor stream and the software that moves it into the trial database.

No timelines, pilot studies, or named therapeutic areas appear in the public statement. The companies describe the effort as an expansion of existing wearable use in research rather than a new product launch.

Why it matters

The arrangement gives Samsung a route into a market—regulated clinical evidence—that has historically resisted consumer electronics. For sponsors and CROs, the test will be whether the data quality and audit trails satisfy FDA or EMA reviewers; consumer-grade sensors have cleared that bar in isolated cases but remain the exception. If the partnership produces even one registrational trial that relies primarily on wearable endpoints, other device makers will face pressure to match the same documentation and validation work. Until then, the announcement remains an intent rather than a delivered capability.

---

Sources:

• Samsung Newsroom

{
  "excerpt": "Samsung will supply wearable biometric streams to Alcedis-run trials in an effort to lower cost and shorten timelines for clinical evidence.",
  "suggestedSection": "business",
  "suggestedTags": ["samsung", "wearables", "clinical-trials", "alcedis"],
  "imagePrompt": "A single abstract wrist-worn sensor rests on a neutral surface beside stacked clinical binders and faint data lines, soft studio light catching matte plastic and paper edges. muted color palette, cinematic lighting, 16:9"
}